Novartis confirmed in published reports today that it has appointed Ludwig Hantson to head its US pharmaceuticals business.
Hantson reports to Joe Jimenez, CEO of the Basel, Switzerland-based company's pharmaceutical business. Hantson replaces Alex Gorsky, who announced he was leaving Novartis in February.
Hantson most recently served as head of Novartis' specialty pharmaceuticals unit in the US, where he has worked since December 2006.
Novartis also said Paulo Costa, president and CEO of Novartis' US unit, will retire June 30 and be replaced by Gary Rosenthal. Rosenthal is currently CFO of the US pharmaceuticals business.